ELEVAR THERAPEUTICS
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.
ELEVAR THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical Product Design Therapeutics
Founded:
2005-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.elevartherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
801-303-7440
Similar Organizations
Ceptaris Therapeutics
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
NovaRock Biotherapeutics
NovaRock Biotherapeutics biotech company that specializes in the development of antibody therapies for cancer and autoimmune diseases.
Teva Laboratoires
Teva Laboratoires is a laboratory that specializes in the production of generic drugs and specialty neurology.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Key Employee Changes
Official Site Inspections
http://www.elevartherapeutics.com
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Elevar Therapeutics"
Mission and Values - Elevar Therapeutics
As a fully remote and dynamic organization, it is essential that we sustain a fun, collaborative culture where the employee voice is valued. Why? Because better care for our employees can lead to better care for our patients. We offer …See details»
Elevar Therapeutics - LinkedIn
Elevar Therapeutics | 17,262 followers on LinkedIn. Elevating Outcomes, Evolving Therapeutic Potential, Engaging with Purpose | Elevar Therapeutics is a rapidly growing, fully integrated ...See details»
Elevar Therapeutics and Relay Therapeutics Announce Exclusive …
1 day ago Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 …See details»
Elevar Therapeutics Announces New Appointments to its Board of …
Oct 26, 2021 Kate is an exceptional industry leader and her appointment reflects a strategic effort to bring new perspectives, relevant biopharmaceutical experience and leadership …See details»
Elevar Therapeutics Resubmits New Drug Application to FDA
Sep 23, 2024 [email protected] 609-439-3997. Investor Relations Contact. Wade Smith Chief Financial & Business Officer, Elevar Therapeutics [email protected].See details»
Elevar offers $500M biobucks for Relay's rare cancer asset
20 hours ago “Over the course of 2024, we have been streamlining our research organization through a series of changes,” a Relay spokesperson told Fierce at the time. The process is …See details»
Elevar Therapeutics Announces CEO Transition and New Board …
Jul 20, 2021 "I look forward to working closely with the Board, executive leadership team and our very talented employees to transform Elevar into a commercial-stage organization by …See details»
Elevar Therapeutics and Relay Therapeutics Announce Exclusive …
1 day ago [email protected] 609-439-3997. Investor Relations Contact: Wade Smith Chief Financial & Business Officer [email protected]. More in Markets …See details»
Elevar Therapeutics Announces New Appointments to its Board of ...
Oct 26, 2021 Kate is an exceptional industry leader and her appointment reflects a strategic effort to bring new perspectives, relevant biopharmaceutical experience and leadership …See details»
Elevar Therapeutics Announces FDA Acceptance for Filing of
Jul 17, 2023 Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for …See details»
Elevar Therapeutics - PitchBook
Www.elevartherapeutics.com. Formerly Known As. Lifecord International USA, Inc. Ownership Status. Acquired/Merged (Operating Subsidiary) Financing Status. Formerly VC-backed. …See details»
Elevar Therapeutics - Crunchbase Company Profile & Funding
LSK BioPartners, Inc (dba LSK BioPharma) is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco (and Pangyo, South Korea).See details»
Careers - Elevar Therapeutics
Unsolicited resumes will not be accepted by Elevar. If you’re interested in partnering with Elevar, kindly send your contact information, and brief summary of your organization including types of …See details»
Elevar Therapeutics and Relay Therapeutics Announce Exclusive …
1 day ago Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 …See details»
Elevar Therapeutics and Tanner Pharma Group Announce Launch …
Dec 1, 2020 Elevar Therapeutics has offices in Utah, California and South Korea, and additional information is available at www.elevartherapeutics.com. About Tanner Pharma Group.See details»
Elevar Therapeutics - Craft
Elevar Therapeutics has 5 employees across 4 locations and $20 m in total funding,. See insights on Elevar Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Relay Therapeutics and Elevar Therapeutics Announce
1 day ago [email protected] 609-439-3997. Investor Relations Contact: Wade Smith Chief Financial & Business Officer [email protected] ...See details»
Elevar Therapeutics - Overview, News & Similar companies
Aug 21, 2022 Elevar Therapeutics contact info: Phone number: (801) 303-7440 Website: www.elevartherapeutics.com What does Elevar Therapeutics do? Elevar Therapeutics …See details»
Press Releases - Elevar Therapeutics
SALT LAKE CITY, USA., July 20, 2021 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and …See details»
Elevar Therapeutics Submits New Drug Application to FDA for
May 17, 2023 Additional information is available at ElevarTherapeutics.com. Media Contact Rosemary Ostmann Phone: 201-615-7751 Email: [email protected]. TagsSee details»